Androgen receptor acetylation modulates proliferation of castrate-resistant prostate cancer

Erin Heine4, Matthew Schiewer2, Victoria Nolte4, Diane E. Merry1, Scott Dehm3, Karen E. Knudsen2 and Heather L. Montie4

Department of Biochemistry and Molecular Biology1, Departments of Cancer Biology, Urology and Radiation Oncology2, Thomas Jefferson University and Kimmel Cancer Center, Philadelphia, PA; Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN3, Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, PA4

Background
Androgen receptor (AR) lysine residues 630/632/633 are acetylated in response to androgen-binding. An AR mutation that mimics this modification occurs in a subset of prostate cancer patients (K630T), and increased levels of AR acetyltransferases have been observed in some advanced cases. We hypothesize that acetylation contributes to aberrant AR activation in castrate-resistant prostate cancer, contributing to tumor growth and viability.

Methods
Genetic and pharmacologic approaches are being utilized to determine the function of AR acetylation in castrate-resistant disease, both in cell culture and in in vivo models. C4-2 cell lines have been generated within which endogenous AR (shRNA) is stably knocked down and acetylation-mutant AR (acetylation-null, acetylation-mimic, or lysine-intact controls) is expressed. The effect of AR acetylation on castrate-resistant cell growth in culture and tumor growth in vivo has been evaluated. Microarray analysis of cultured cells has been performed to investigate transcriptomic changes that occur when AR acetylation is blocked. Migration assays have been performed based on microarray results. An antibody specific to AR acetylation is being created in order to evaluate this modification in various disease states and with interventions to manipulate it.

Results
Acetylation-null AR expressing C4-2 cells had a substantially reduced growth rate in culture and in xenograft tumors. Mice injected with these cells had a substantially reduced tumor take. Acetylation-mimic AR-expressing cells have a growth advantage over controls in culture, and, in castrated mice, these xenograft tumors grew faster than controls. Microarray revealed gene expression changes in a number of cellular pathways in acetylation-null AR-expressing cells. A member of MMP family was substantially downregulated. As such, we found that acetylation-null expressing C4-2 cells migrate less than controls, and acetylation-mimic expressing C4-2 cells have increased migration over controls. Moreover, pharmacologic activation of an AR deacetylase and pharmacologic inhibition of an AR acetyltransferase reduced growth and induced death of C4-2 cells.

Conclusions
Our data indicate that AR acetylation plays a critical role in castrate-resistant disease and that it may also contribute to a metastatic phenotype. These studies also suggest that targeting the enzymes responsible for AR acetylation may be a viable means to treat castrate-resistant disease.

Conflicts of interest: None to report

Funding sources: PCFYI (John Moran) and PCOM funds (to HLM)